Shellback Capital LP Invests $22.55 Million in Thermo Fisher Scientific Inc. $TMO

Key Points

• Shellback Capital LP acquired 45,322 shares of Thermo Fisher Scientific for about $22.6 million, marking it as the company's 16th largest holding.
• Thermo Fisher Scientific's stock has an average price target of $589.38, with 16 analysts rating it as a Buy and 6 as a Hold.
• The company recently reported quarterly earnings of $5.36 EPS, exceeding estimates, and announced a quarterly dividend of $0.43 per share.

Shellback Capital LP bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 45,322 shares of the medical research company's stock, valued at approximately $22,552,000. Thermo Fisher Scientific makes up approximately 2.2% of Shellback Capital LP's holdings, making the stock its 16th biggest holding.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Thermo Fisher Scientific by 0.7% during the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after buying an additional 230,382 shares during the last quarter. Amundi boosted its holdings in Thermo Fisher Scientific by 5.9% during the first quarter. Amundi now owns 3,029,044 shares of the medical research company's stock worth $1,426,316,000 after buying an additional 168,197 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Thermo Fisher Scientific by 4.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after buying an additional 115,463 shares during the last quarter. Pictet Asset Management Holding SA boosted its holdings in Thermo Fisher Scientific by 7.2% during the first quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after buying an additional 193,378 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Thermo Fisher Scientific by 11.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,420,949 shares of the medical research company's stock worth $1,259,450,000 after buying an additional 257,462 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,066 shares of company stock worth $14,182,963. Corporate insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. HSBC restated a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Raymond James Financial restated an "outperform" rating and set a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Finally, Barclays upgraded shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $490.00 to $550.00 in a report on Thursday. Seventeen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $592.24.

Thermo Fisher Scientific Stock Up 3.1%

NYSE TMO traded up $14.75 during trading on Thursday, hitting $491.29. The stock had a trading volume of 937,331 shares, compared to its average volume of 2,399,979. The company has a market capitalization of $185.52 billion, a PE ratio of 28.41, a P/E/G ratio of 2.58 and a beta of 0.75. The company's 50-day moving average price is $464.58 and its two-hundred day moving average price is $452.37. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business's quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.